SILO PHARMA INC (SILO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SILO • US82711P2011

0.3058 USD
+0.02 (+6.55%)
Last: Feb 6, 2026, 08:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SILO. SILO was compared to 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SILO as it has an excellent financial health rating, but there are worries on the profitability. SILO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • SILO had negative earnings in the past year.
  • SILO had a negative operating cash flow in the past year.
  • In the past 5 years SILO reported 4 times negative net income.
  • In the past 5 years SILO always reported negative operating cash flow.
SILO Yearly Net Income VS EBIT VS OCF VS FCFSILO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

  • SILO's Return On Assets of -79.51% is on the low side compared to the rest of the industry. SILO is outperformed by 66.60% of its industry peers.
  • SILO has a Return On Equity of -101.36%. This is comparable to the rest of the industry: SILO outperforms 45.80% of its industry peers.
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROIC N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
SILO Yearly ROA, ROE, ROICSILO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

  • The Gross Margin of SILO (65.42%) is better than 80.34% of its industry peers.
  • In the last couple of years the Gross Margin of SILO has grown nicely.
  • SILO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
SILO Yearly Profit, Operating, Gross MarginsSILO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SILO has more shares outstanding
  • SILO has more shares outstanding than it did 5 years ago.
  • SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SILO Yearly Shares OutstandingSILO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SILO Yearly Total Debt VS Total AssetsSILO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • SILO has an Altman-Z score of -4.12. This is a bad value and indicates that SILO is not financially healthy and even has some risk of bankruptcy.
  • SILO has a Altman-Z score (-4.12) which is in line with its industry peers.
  • There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC8.86%
SILO Yearly LT Debt VS Equity VS FCFSILO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

  • A Current Ratio of 8.70 indicates that SILO has no problem at all paying its short term obligations.
  • SILO's Current ratio of 8.70 is fine compared to the rest of the industry. SILO outperforms 77.29% of its industry peers.
  • A Quick Ratio of 8.70 indicates that SILO has no problem at all paying its short term obligations.
  • SILO's Quick ratio of 8.70 is fine compared to the rest of the industry. SILO outperforms 77.29% of its industry peers.
Industry RankSector Rank
Current Ratio 8.7
Quick Ratio 8.7
SILO Yearly Current Assets VS Current LiabilitesSILO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • SILO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.56%, which is quite impressive.
  • The Revenue has decreased by 0.00% in the past year.
  • SILO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.51% yearly.
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%

3.2 Future

  • SILO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.62% yearly.
  • SILO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by 0.00% yearly.
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SILO Yearly Revenue VS EstimatesSILO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
SILO Yearly EPS VS EstimatesSILO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILO Price Earnings VS Forward Price EarningsSILO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILO Per share dataSILO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • SILO's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SILO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SILO PHARMA INC

NASDAQ:SILO (2/6/2026, 8:06:12 PM)

0.3058

+0.02 (+6.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-26
Inst Owners11.65%
Inst Owner Change0.33%
Ins Owners1.67%
Ins Owner Change8.56%
Market Cap4.07M
Revenue(TTM)72.00K
Net Income(TTM)-5.08M
Analysts82.86
Price TargetN/A
Short Float %4.53%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.57
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS0.38
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.42%
FCFM N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.7
Quick Ratio 8.7
Altman-Z -4.12
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.95%
OCF growth 3YN/A
OCF growth 5YN/A

SILO PHARMA INC / SILO FAQ

What is the fundamental rating for SILO stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILO.


What is the valuation status of SILO PHARMA INC (SILO) stock?

ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.


Can you provide the profitability details for SILO PHARMA INC?

SILO PHARMA INC (SILO) has a profitability rating of 2 / 10.


What is the earnings growth outlook for SILO PHARMA INC?

The Earnings per Share (EPS) of SILO PHARMA INC (SILO) is expected to decline by -25% in the next year.